4 Healthcare Stock Stories Making a Monday Buzz
Eli Lilly and Co. (NYSE:LLY): Closing price $52.79
Lilly, facing a patent cliff of forbidding proportions, might get a $15-billion break if it can manage to win a closely observed patent battle with the generic drugmaker Teva Pharmaceutical Industries. Although many do not expect Lilly to win, several patent attorneys and industry analysts opine that the patent being challenged by Teva, starting Monday in Indianapolis federal court, will “pass legal muster.”
Last summer, the United States Court of Appeals in Washington upheld the validity of the basic patent on the chemical structure of Alimta, which protected Lilly’s $2.6 billion-a-year lung cancer drug from generics until January 2017.